Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-98 trial

Annals of Oncology

Volumn 19, Issue 11, 2008, Pages 1837-1841

  Pestalozzi, Bernhard C ^a   Francis, P ^b   Quinaux, E ^c   Dolci, S ^d,e   Azambuja, E ^d,e   Gelber, R D ^f   Viale, G ^g   Balil, A ^h,i   Andersson, M ^j,k   Nordenskjod B ^l,m   Gnant, M ^n,o   Gutierrez, J ^p,q   Lang I ^r   Crown, J P A ^s,t   Piccart Gebhart, M ^d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^d JULES BORDET INSTITUTE   (Belgium)

^e Breast European Adjuvant Study Team (BrEAST) Data Centre   (Belgium)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g UNIVERSITY OF MILAN   (Italy)

^h HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

ⁱ Grupo Español de Investigación de Cáncer de Mama   (Spain)

^j Rigshospitalet   (Denmark)

^k Danish Breast Cancer Cooperative Group   (Denmark)

^l LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^m Scandinavian Breast Cancer Group   (Sweden)

ⁿ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^o Austrian Breast and Colorectal Cancer Study Group   (Austria)

^p CLÍNICA LAS CONDES   (Chile)

^q Grupo Oncológico Cooperativo Chileno de Investi gación GOCCHI   (Chile)

^r NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^s ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^t All Ireland Cooperative Oncology Research Group   (Ireland)

more..

Author keywords

Adjuvant chemotherapy; Breast cancer; Central nervous system; Meningeal carcinomatosis; Taxane; Trastuzumab

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; METHOTREXATE;

ADJUVANT THERAPY; ADULT; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE SEQUENCE; DRUG RESPONSE; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENINGEAL METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME;

EID: 54949136570     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn385     Document Type: Article

References (14)

1. Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365: 1687-1717.
2. Goldhirsch A, Wood WC, Gelber RD et al. Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007; 18: 1133-1144.
3. National Comprehensive Cancer Network. www.nccn.org (5 June 2008, date last accessed).
4. Francis P, Crown J, Di Leo A et al. on behalf of the BIG 02-98 Collaborative Group. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst. 2008; 100: 121-133.
5. Freilich W, Seidman AD, DeAngelis LM. Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel. Cancer 1995; 76: 232-236.
6. Crivellari D, Pagani O, Veronesi A et al. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Onool. 2001; 12: 353-356.
7. Pestalozzi BC, Zahrieh D, Price KN et al. for the International Breast Cancer Study Group (IBCSG). Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol. 2006; 17: 935-944.
8. Gonzales-Angulo AM, Cristofanilli M, Strom EA et al. Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer 2004; 101: 1760-1766.
9. Carey LA, Ewend MG, Metzger R et al. Central nervous system metastases in women after multimodality therapy for high risk breast cancer. Breast Cancer Res Treat. 2004; 88: 273-280.
10. Bendell JC, Domchek S, Burstein HJ et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97: 2972-2977.
11. Burstein HJ, Lieberman G, Slamon DJ et al. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol, 2005; 16(11): 1772-1777.
12. Dawson SJ, Ranieri NF, Snyder RD et al. Central nervous system metastases in women with HER-2 positive metastatic breast cancer after treatment with trastuzumab. Asia Pac J Clin Oncol. 2006; 2: 50-56.
13. Minn AJ, Kang Y, Serganova I et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest. 2005; 115: 44-55.
14. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol. 2000; 18:2350-2351.